Telomir Pharmaceuticals, Inc. (TELO)
NASDAQ: TELO · Real-Time Price · USD
3.230
-0.720 (-18.23%)
At close: Mar 31, 2025, 4:00 PM
3.378
+0.148 (4.57%)
Pre-market: Apr 1, 2025, 5:26 AM EDT

Telomir Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-16.53-13.07-0.85-0.14
Other Amortization
4.341.61--
Stock-Based Compensation
6.87---
Other Operating Activities
-7.49--
Change in Accounts Payable
0.180.110.390.02
Change in Other Net Operating Assets
-0.06-0--
Operating Cash Flow
-5.07-3.86-0.47-0.12
Short-Term Debt Issued
-3.120.460.12
Total Debt Issued
-3.120.460.12
Short-Term Debt Repaid
-0.53---
Total Debt Repaid
-0.53---
Net Debt Issued (Repaid)
-0.533.120.460.12
Issuance of Common Stock
6.8710.06-
Other Financing Activities
--0.26-0.05-
Financing Cash Flow
6.343.860.470.12
Net Cash Flow
1.26-00-
Levered Free Cash Flow
1.1-1.96--
Unlevered Free Cash Flow
-0.53-2.55--
Change in Net Working Capital
-0.260.08--
Updated Feb 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q